miR-497-5p Enhances the Chemosensitivity of Non-Small Cell Lung Cancer Cells to Cisplatin via Targeting of the CDCA4 Gene

Nasir Azam; Shuo Yang; Khalil Ur Rahman; Jiawen Yu; Chunhui Zhao*; Bin Feng*

Nasir Azam, Shuo Yang, Khalil Ur Rahman, Jiawen Yu, Chunhui Zhao* and Bin Feng*

Volume3-Issue4
Dates: Received: 2022-04-14 | Accepted: 2022-04-21 | Published: 2022-04-22
Pages: 373-384

Abstract

Non-Small Cell Lung Cancer (N-SCLC) accounts for almost 85% of all diagnosed lung cancer and the prognosis remains poor usually because of assimilated drug resistance including cisplatin. The miR-497-5p family has been discovered to play a significant role in regulating biological functions in N-SCLC. The purpose of this study was to investigate the molecular mechanism of miR-497-5p and its target gene on modulating cisplatin chemosensitivity in N-SCLC cells. The enhanced chemosensitivity effect of miR-497-5p to cisplatin in A549 and H1299 cells was detected by MTT method. Dual luciferase reporter assay, quantitative Real-Time PCR (qRT-PCR) and Western blotting were performed to demonstrate that miR-497-5p directly targets CDCA4 to reduce the expression. Transwell, colony formation and ﬂow cytometry assays showed that combination of miR-497-5p and cisplatin exerted stronger effects on inhibiting N-SCLC cells proliferation, migration and invasion as well as promoting apoptosis and G1 phase arrest than miR-497-5p and cisplatin alone. The same tendency was observed in the upregulation of apoptosis-related protein Bax and Cytochrome-C and downregulation of cycle-related proteins CyclinB1 and CDK1. Our results indicate that upregulation of miR-497-5p targets CDCA4 directly and may function as an important modifier to sensitize N-SCLC cells to cisplatin.

FullText HTML FullText PDF DOI: 10.37871/jbres1451

Certificate of Publication

Copyright

How to cite this article

Azam N, Yang S, Ur Rahman K, Yu J, Zhao C, Feng B. miR-497-5p Enhances the Chemosensitivity of Non-Small Cell Lung Cancer Cells to Cisplatin via Targeting of the CDCA4 Gene. J Biomed Res Environ Sci. 2022 Apr 22; 3(4): 373-384. doi: 10.37871/jbres1451, Article ID: JBRES1451, Available at: https://www.jelsciences.com/articles/jbres1451.pdf

Subject area(s)

References

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25. PMID: 26808342.
Ferguson MK. Diagnosing and staging of non-small cell lung cancer. Hematol Oncol Clin North Am. 1990 Dec;4(6):1053-68. PMID: 1962775.
Judson I, Kelland LR. New developments and approaches in the platinum arena. Drugs. 2000;59 Suppl 4:29-36; discussion 37-8. doi: 10.2165/00003495-200059004-00004. PMID: 10864228.
Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012 Jul;64(3):706-21. doi: 10.1124/pr.111.005637. Epub 2012 Jun 1. PMID: 22659329; PMCID: PMC3400836.
van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 2011 Aug 5;11(9):644-56. doi: 10.1038/nrc3107. PMID: 21822212.
Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006 Nov;6(11):857-66. doi: 10.1038/nrc1997. PMID: 17060945.
Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol. 2011 Mar;6(3):482-8. doi: 10.1097/JTO.0b013e318208c785. PMID: 21258252.
Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, Tucker MA, Bertazzi PA, Pesatori AC, Caporaso NE, McShane LM, Wang E. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 2010 Jan 15;16(2):430-41. doi: 10.1158/1078-0432.CCR-09-1736. Epub 2010 Jan 12. PMID: 20068076; PMCID: PMC3163170.
Gasparini P, Cascione L, Landi L, Carasi S, Lovat F, Tibaldi C, Alì G, D'Incecco A, Minuti G, Chella A, Fontanini G, Fassan M, Cappuzzo F, Croce CM. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14924-9. doi: 10.1073/pnas.1520329112. Epub 2015 Nov 16. PMID: 26627242; PMCID: PMC4672770.
Cui R, Meng W, Sun HL, Kim T, Ye Z, Fassan M, Jeon YJ, Li B, Vicentini C, Peng Y, Lee TJ, Luo Z, Liu L, Xu D, Tili E, Jin V, Middleton J, Chakravarti A, Lautenschlaeger T, Croce CM. MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer. Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4288-97. doi: 10.1073/pnas.1502068112. Epub 2015 Jul 17. PMID: 26187928; PMCID: PMC4534291.
Kang M, Shi J, Peng N, He S. MicroRNA-211 promotes non-small-cell lung cancer proliferation and invasion by targeting MxA. Onco Targets Ther. 2017 Nov 28;10:5667-5675. doi: 10.2147/OTT.S143084. PMID: 29238200; PMCID: PMC5713696.
Wang C, Wang S, Ma F, Zhang W. miRNA‑328 overexpression confers cisplatin resistance in non‑small cell lung cancer via targeting of PTEN. Mol Med Rep. 2018 Nov;18(5):4563-4570. doi: 10.3892/mmr.2018.9478. Epub 2018 Sep 12. PMID: 30221716.
Chen Y, Kuang D, Zhao X, Chen D, Wang X, Yang Q, Wan J, Zhu Y, Wang Y, Zhang S, Wang Y, Tang Q, Masuzawa M, Wang G, Duan Y. miR-497-5p inhibits cell proliferation and invasion by targeting KCa3.1 in angiosarcoma. Oncotarget. 2016 Sep 6;7(36):58148-58161. doi: 10.18632/oncotarget.11252. PMID: 27531900; PMCID: PMC5295420.
Chai L, Kang XJ, Sun ZZ, Zeng MF, Yu SR, Ding Y, Liang JQ, Li TT, Zhao J. MiR-497-5p, miR-195-5p and miR-455-3p function as tumor suppressors by targeting hTERT in melanoma A375 cells. Cancer Manag Res. 2018 May 3;10:989-1003. doi: 10.2147/CMAR.S163335. PMID: 29760567; PMCID: PMC5937487.
Zhu D, Tu M, Zeng B, Cai L, Zheng W, Su Z, Yu Z. Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2. Cancer Med. 2017 Feb;6(2):452-462. doi: 10.1002/cam4.987. Epub 2017 Jan 8. PMID: 28064447; PMCID: PMC5313645.
Watanabe-Fukunaga R, Iida S, Shimizu Y, Nagata S, Fukunaga R. SEI family of nuclear factors regulates p53-dependent transcriptional activation. Genes Cells. 2005 Aug;10(8):851-60. doi: 10.1111/j.1365-2443.2005.00881.x. PMID: 16098148.
Wang L, Zhu G, Yang D, Li Q, Li Y, Xu X, He D, Zeng C. The spindle function of CDCA4. Cell Motil Cytoskeleton. 2008 Jul;65(7):581-93. doi: 10.1002/cm.20286. PMID: 18498124.
Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem. 2019 Jul;88:102925. doi: 10.1016/j.bioorg.2019.102925. Epub 2019 Apr 11. PMID: 31003078.
Wood RD, Araújo SJ, Ariza RR, Batty DP, Biggerstaff M, Evans E, Gaillard PH, Gunz D, Köberle B, Kuraoka I, Moggs JG, Sandall JK, Shivji MK. DNA damage recognition and nucleotide excision repair in mammalian cells. Cold Spring Harb Symp Quant Biol. 2000;65:173-82. doi: 10.1101/sqb.2000.65.173. PMID: 12760031.
Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003 Mar 15;63(6):1311-6. PMID: 12649192.
Wu SG, Chang TH, Liu YN, Shih JY. MicroRNA in Lung Cancer Metastasis. Cancers (Basel). 2019 Feb 23;11(2):265. doi: 10.3390/cancers11020265. PMID: 30813457; PMCID: PMC6406837.
Chen Y, Gao Y, Zhang K, Li C, Pan Y, Chen J, Wang R, Chen L. MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer. Cell Physiol Biochem. 2015;37(5):1869-80. doi: 10.1159/000438548. Epub 2015 Nov 17. PMID: 26584286.
Xia Y, Hu C, Lian L, Hui K, Wang L, Qiao Y, Liu L, Liang L, Jiang X. miR‑497 suppresses malignant phenotype in non‑small cell lung cancer via targeting KDR. Oncol Rep. 2019 Jul;42(1):443-452. doi: 10.3892/or.2019.7163. Epub 2019 May 16. PMID: 31115562.
Huang Q, Li H, Dai X, Zhao D, Guan B, Xia W. miR‑497 inhibits the proliferation and migration of A549 non‑small‑cell lung cancer cells by targeting FGFR1. Mol Med Rep. 2019 Oct;20(4):3959-3967. doi: 10.3892/mmr.2019.10611. Epub 2019 Aug 23. PMID: 31485617.
Li G, Wang K, Wang J, Qin S, Sun X, Ren H. miR-497-5p inhibits tumor cell growth and invasion by targeting SOX5 in non-small-cell lung cancer. J Cell Biochem. 2019 Jun;120(6):10587-10595. doi: 10.1002/jcb.28345. Epub 2019 Feb 28. PMID: 30816573.
Yin Q, Han Y, Zhu D, Li Z, Shan S, Jin W, Lu Q, Ren T. miR-145 and miR-497 suppress TGF-β-induced epithelial-mesenchymal transition of non-small cell lung cancer by targeting MTDH. Cancer Cell Int. 2018 Jul 27;18:105. doi: 10.1186/s12935-018-0601-4. PMID: 30065618; PMCID: PMC6062944.
Huang C, Ma R, Yue J, Li N, Li Z, Qi D. MiR-497 Suppresses YAP1 and Inhibits Tumor Growth in Non-Small Cell Lung Cancer. Cell Physiol Biochem. 2015;37(1):342-52. doi: 10.1159/000430358. Epub 2015 Aug 24. PMID: 26316081.
Huang X, Wang L, Liu W, Li F. MicroRNA-497-5p inhibits proliferation and invasion of non-small cell lung cancer by regulating FGF2. Oncol Lett. 2019 Mar;17(3):3425-3431. doi: 10.3892/ol.2019.9954. Epub 2019 Jan 21. PMID: 30867780; PMCID: PMC6396182.
Xu C, Li S, Chen T, Hu H, Ding C, Xu Z, Chen J, Liu Z, Lei Z, Zhang HT, Li C, Zhao J. miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer. Oncol Rep. 2016 Jan;35(1):497-503. doi: 10.3892/or.2015.4392. Epub 2015 Nov 4. PMID: 26549165.
Ma W, Feng W, Tan J, Xu A, Hu Y, Ning L, Kang Y, Wang L, Zhao Z. miR-497 may enhance the sensitivity of non-small cell lung cancer cells to gefitinib through targeting the insulin-like growth factor-1 receptor. J Thorac Dis. 2018 Oct;10(10):5889-5897. doi: 10.21037/jtd.2018.10.40. PMID: 30505497; PMCID: PMC6236188.
Wang L, Ji XB, Wang LH, Qiu JG, Zhou FM, Liu WJ, Wan DD, Lin MC, Liu LZ, Zhang JY, Jiang BH. Regulation of MicroRNA-497-Targeting AKT2 Influences Tumor Growth and Chemoresistance to Cisplatin in Lung Cancer. Front Cell Dev Biol. 2020 Sep 8;8:840. doi: 10.3389/fcell.2020.00840. PMID: 33015042; PMCID: PMC7505950.
Guo D, Wang Y, Ren K, Han X. Knockdown of LncRNA PVT1 inhibits tumorigenesis in non-small-cell lung cancer by regulating miR-497 expression. Exp Cell Res. 2018 Jan 1;362(1):172-179. doi: 10.1016/j.yexcr.2017.11.014. Epub 2017 Nov 11. PMID: 29133127.
Li Z, Lu Q, Zhu D, Han Y, Zhou X, Ren T. Lnc-SNHG1 may promote the progression of non-small cell lung cancer by acting as a sponge of miR-497. Biochem Biophys Res Commun. 2018 Nov 30;506(3):632-640. doi: 10.1016/j.bbrc.2018.10.086. Epub 2018 Oct 25. PMID: 30454699.
Qin S, Zhao Y, Lim G, Lin H, Zhang X, Zhang X. Circular RNA PVT1 acts as a competing endogenous RNA for miR-497 in promoting non-small cell lung cancer progression. Biomed Pharmacother. 2019 Mar;111:244-250. doi: 10.1016/j.biopha.2018.12.007. Epub 2018 Dec 24. PMID: 30590312.
Xu SH, Bo YH, Ma HC, Zhang HN, Shao MJ. lncRNA LINC00473 promotes proliferation, migration, invasion and inhibition of apoptosis of non-small cell lung cancer cells by acting as a sponge of miR-497-5p. Oncol Lett. 2021 Jun;21(6):429. doi: 10.3892/ol.2021.12690. Epub 2021 Mar 30. PMID: 33868467; PMCID: PMC8045175.
Han Z, Zhang Y, Yang Q, Liu B, Wu J, Zhang Y, Yang C, Jiang Y. miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget. 2015 May 30;6(15):13149-63. doi: 10.18632/oncotarget.3693. PMID: 25909221; PMCID: PMC4537005.
Tian ZS, Yan MJ, Li S, Cong D, Wang YY, Zhu QS. miR-497 inhibits tumor growth and migration of osteosarcoma by targeting plexinA4 and CDK6. Neoplasma. 2020 Sep;67(5):1122-1130. doi: 10.4149/neo_2020_200108N26. Epub 2020 Jul 2. PMID: 32614239.
Abdullah JM, Jing X, Spassov DS, Nachtman RG, Jurecic R. Cloning and characterization of Hepp, a novel gene expressed preferentially in hematopoietic progenitors and mature blood cells. Blood Cells Mol Dis. 2001 May-Jun;27(3):667-76. doi: 10.1006/bcmd.2001.0434. PMID: 11482882.
Pang S, Xu Y, Chen J, Li G, Huang J, Wu X. Knockdown of cell division cycle-associated protein 4 expression inhibits proliferation of triple negative breast cancer MDA-MB-231 cells in vitro and in vivo. Oncol Lett. 2019 May;17(5):4393-4400. doi: 10.3892/ol.2019.10077. Epub 2019 Feb 26. PMID: 30944632; PMCID: PMC6444385.
Hayashi R, Goto Y, Ikeda R, Yokoyama KK, Yoshida K. CDCA4 is an E2F transcription factor family-induced nuclear factor that regulates E2F-dependent transcriptional activation and cell proliferation. J Biol Chem. 2006 Nov 24;281(47):35633-48. doi: 10.1074/jbc.M603800200. Epub 2006 Sep 19. PMID: 16984923.
Xu Y, Wu X, Li F, Huang D, Zhu W. CDCA4, a downstream gene of the Nrf2 signaling pathway, regulates cell proliferation and apoptosis in the MCF‑7/ADM human breast cancer cell line. Mol Med Rep. 2018 Jan;17(1):1507-1512. doi: 10.3892/mmr.2017.8095. Epub 2017 Nov 15. PMID: 29257222; PMCID: PMC5780089.
Alderman C, Sehlaoui A, Xiao Z, Yang Y. MicroRNA-15a inhibits the growth and invasiveness of malignant melanoma and directly targets on CDCA4 gene. Tumour Biol. 2016 Oct;37(10):13941-13950. doi: 10.1007/s13277-016-5271-z. Epub 2016 Aug 4. PMID: 27492455.
Liu J, Tao G, Zhong C, Liu X. Upregulation of miR-29c-3p Hinders Melanoma Progression by Inhibiting CDCA4 Expression. Biomed Res Int. 2021 Aug 28;2021:7065963. doi: 10.1155/2021/7065963. PMID: 34497853; PMCID: PMC8419494.